sur SANOFI-AVENTIS (EPA:SAN)
Sanofi's Infilbray Gains FDA Approval for Type 3 Gaucher Disease Neurological Symptoms
Sanofi's Infilbray, an oral medication, has been approved by the US FDA to treat neurological manifestations of Type 3 Gaucher disease (GD3). This marks a first in addressing the central nervous system (CNS) issues associated with this chronic form of Gaucher disease. GD3 leads to both systemic and neurologic decline.
The approval was based on the LEAP2MONO phase 3 study, which demonstrated Infilbray's superiority over enzyme replacement therapy in improving neurological symptoms. Patients showed significant progress in cognitive and motor functions.
Infilbray's approval is seen as a crucial development for GD3 patients facing limited therapeutic options for neurological symptoms. With prior designations for breakthrough therapy, rare pediatric disease, and fast-track review, Infilbray is set to expand its global regulatory reach in the coming years.
R. P.
Copyright © 2026 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de SANOFI-AVENTIS